AGTR1 and cancer: The precise biological mechanisms underlying the protective effects of ACEIs or ARBs against cancer development is that the angiotensin I–VII levels increase during the inhibition of the ACE–angiotensin II–angiotensin II type 1 receptor (AT1R) axis, resulting in the activation of the Mas receptor and subsequent inhibition of cell proliferation and angiogenesis [27, 28].